PRR25 inhibitors are a class of compounds that selectively target and inhibit the activity of the proline-rich protein 25 (PRR25). This protein belongs to the larger family of proline-rich proteins, which are characterized by their high content of proline residues. PRR25 is a protein that plays a role in various cellular processes, particularly those involving signal transduction and protein-protein interactions. Due to its structure, PRR25 is involved in mediating interactions between proteins through its proline-rich domains, which are recognized by SH3 (Src Homology 3) domains and other proline-binding motifs present in many signaling molecules. The inhibition of PRR25 affects these protein interactions and can modulate various intracellular signaling pathways that depend on these interactions.
The development of PRR25 inhibitors often involves screening for molecules that can specifically bind to the proline-rich regions of the PRR25 protein, thereby blocking its ability to engage with its interacting partners. Structurally, many PRR25 inhibitors mimic the proline-rich motifs or adopt conformations that can compete for binding with SH3 or other domains, effectively disrupting the natural interaction network of PRR25 within the cell. This disruption can have downstream effects on the signaling cascades and pathways that PRR25 is a part of, leading to alterations in cellular function. These inhibitors are often designed using insights from the protein's three-dimensional structure and the dynamics of its interaction with other cellular proteins. As a result, the structural complexity and specificity of PRR25 inhibitors reflect the intricate role that PRR25 plays in cellular signaling mechanisms.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
A potent kinase inhibitor that can inhibit protein kinases that may phosphorylate PRR25 or its interacting partners. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $40.00 $82.00 $256.00 | 127 | |
Inhibits eukaryotic protein synthesis which can lead to a decrease in PRR25 expression levels. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $73.00 $238.00 $717.00 $2522.00 $21420.00 | 53 | |
Binds to DNA and inhibits RNA synthesis which can downregulate PRR25 transcription. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A PI3K inhibitor that can affect AKT signaling and potentially alter PRR25 activity if it is PI3K/AKT pathway-dependent. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that can affect cell growth and proliferation pathways possibly involving PRR25. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
Inhibits MEK and can affect the MAPK/ERK pathway which may modulate PRR25's role if it is part of this pathway. | ||||||
Calphostin C | 121263-19-2 | sc-3545 sc-3545A | 100 µg 1 mg | $336.00 $1642.00 | 20 | |
A PKC inhibitor that can alter signal transduction potentially affecting PRR25's function if it is PKC-dependent. | ||||||
Chelerythrine chloride | 3895-92-9 | sc-3547 sc-3547A | 5 mg 25 mg | $88.00 $311.00 | 17 | |
Another PKC inhibitor that can change signaling pathways involving PRR25 through PKC modulation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A p38 MAPK inhibitor which can affect stress response pathways potentially involving PRR25. | ||||||
W-7 | 61714-27-0 | sc-201501 sc-201501A sc-201501B | 50 mg 100 mg 1 g | $163.00 $300.00 $1642.00 | 18 | |
A calmodulin antagonist that can affect calcium signaling and potentially impact PRR25's function if calmodulin-dependent. | ||||||